ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

IMURAN
Arthritis/rheumatic disorders
Organ rejection prophylaxis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

IMURAN Rx

Generic Name and Formulations:
Azathioprine 50mg; scored tabs.

Company:
Prometheus Labs, Inc.

Therapeutic Use:

Indications for IMURAN:

To reduce signs/symptoms of active rheumatoid arthritis.

Adult:

1mg/kg per day in 1–2 divided doses. After 6–8 weeks, if needed, increase by 0.5mg/kg per day increments every 4 weeks; max 2.5mg/kg per day. Maintenance: use lowest effective dose; can decrease by 0.5mg/kg per day (approx. 25mg daily) every 4 weeks. May continue use of aspirin, NSAIDs, and/or low dose steroids during therapy.

Children:

Not established.

Contraindications:

Pregnancy (Cat.D). Prior treatment with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan, others) increases malignancy risk.

Warnings/Precautions:

Be fully familiar with this product's toxicity before use. Increased risk of lymphoma, other malignancies (esp. skin), or serious infections (eg, bacterial, viral, fungal, protozoal, opportunistic, including reactivation of latent ones). Avoid sun, UV light. Not for treating Crohn’s disease or ulcerative colitis. Impaired renal function. Monitor CBCs with platelets weekly during 1st month, then twice monthly for 2nd and 3rd months, then monthly or more frequently during dose adjustments. Consider TPMT testing to identify those at increased risk of myelotoxicity; if low or absent TPMT activity results, use alternative therapies. Nursing mothers: not recommended.

Interactions:

See Contraindications. Reduce dose to ⅓ or ¼ with allopurinol. Anemia, leukopenia with ACE inhibitors. Pancytopenia, myelotoxicity with ribavirin. Exaggerated leukopenia with cotrimoxazole. Caution with concomitant aminosalicylates (eg, sulfasalazine, mesalazine, olsalazine). May antagonize warfarin. Concomitant DMARDs: not recommended.

Pharmacological Class:

Immunosuppressant (antimetabolite).

Adverse Reactions:

Severe leukopenia, thrombocytopenia, anemia, pancytopenia, bone marrow suppression, secondary infection, GI toxicity, mutagenic and carcinogenic potential, pancreatitis, hepatotoxicity, rash, alopecia; progressive multifocal leukoencephalopathy (consider reducing dose).

How Supplied:

Tabs—100

Indications for IMURAN:

Adjunct for the prevention of rejection in renal homotransplantation.

Adult:

Individualized. 3–5mg/kg once daily starting day of, or in some cases 1–3 days before, transplant. Maintenance: may reduce to 1–3mg/kg daily.

Children:

Not established.

Warnings/Precautions:

Be fully familiar with this product's toxicity before use. Increased risk of lymphoma, other malignancies (esp. skin), or serious infections (eg, bacterial, viral, fungal, protozoal, opportunistic, including reactivation of latent ones). Avoid sun, UV light. Impaired renal function. Monitor CBCs with platelets weekly during 1st month, then twice monthly for 2nd and 3rd months, then monthly or more frequently during dose adjustments. Consider TPMT testing to identify those at increased risk of myelotoxicity; if low or absent TPMT activity results, use alternative therapies. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:

Reduce dose to ⅓ or ¼ with allopurinol. Anemia, leukopenia with ACE inhibitors. Pancytopenia, myelotoxicity with ribavirin. Exaggerated leukopenia with cotrimoxazole. Caution with concomitant aminosalicylates (eg, sulfasalazine, mesalazine, olsalazine). May antagonize warfarin.

Pharmacological Class:

Immunosuppressant (antimetabolite).

Adverse Reactions:

Severe leukopenia, thrombocytopenia, anemia, pancytopenia, bone marrow suppression, secondary infection, GI toxicity, mutagenic and carcinogenic potential, pancreatitis, hepatotoxicity, rash, alopecia; progressive multifocal leukoencephalopathy (consider reducing dose).

How Supplied:

Tabs—100

Sign Up for Free e-Newsletters

CME Focus